A new analysis spotlights the top 20 drugs in the late-stage pipeline

The new cystic fibrosis triplet from Vertex ranks as the single most valuable late-stage therapy in the global pipeline, according to a new report from Vantage, the editorial arm of Evaluate. And they are way out ahead on the net present value scale used to rank these would-be blockbusters.

In this ranking, which you can see in full below, the Vertex triplet including VX-659 has a net present value — or NPV — of $14.4 billion as Phase III data loom, calculating costs and potential revenue.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 50,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->